Benjamin Graham fit · Defensive deep-value investing
Is Indivior Pharmaceuticals Inc (INDV) a Benjamin Graham Stock?
Meets only 1/7 Graham criteria - likely overpriced or unstable.
30/100
FNot a fit
1/7 criteria passed
+8 sector-quality lift. Top-quintile within its sector on 4 of 5 quality metrics. Raw pillar score 22 → lifted to 30 before grade derivation.
Benjamin Graham's Criteria, Applied to INDV
P/E ≤ 15
key19.0x
P/B ≤ 1.5
key-
Current ratio ≥ 2
0.9x
Debt / Equity ≤ 1
-
5y profitable
keyNo
Earnings yield ≥ 7%
5.3%
Revenue growing
11.9%
How INDV Scores on Other Strategies
Live Financial Snapshot
Market cap
$4.12B
P/E (TTM)
19.0x
ROIC (TTM)
85.68%
Gross margin
83.11%
Other Benjamin Graham fit reports
Frequently Asked Questions
What is INDV's Benjamin Graham fit score?
INDV scores 30/100 on our Benjamin Graham fit engine - grade F. Meets only 1/7 Graham criteria - likely overpriced or unstable.
Does Benjamin Graham actually own INDV?
Our score is computed from financial fundamentals against Benjamin Graham's published criteria. We don't claim that Benjamin Graham personally owns or recommends INDV.
How often is this score updated?
INDV's Benjamin Graham fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Key terms in this analysis
Educational tool, not investment advice. Scores are computed from publicly-available financial data against published investing-strategy criteria. We do not claim that Benjamin Graham personally owns or recommends INDV.